


SHEET 1 OF 2

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies; Lo; Lan; Wesolowski SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999 GROUP					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
	A1	5,908,626	June 1, 1999	Hybrid with Interferon- and an Immunoglobulin Fc Joined by a Peptide Linker	424- 134.1				
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
	B1	WO 92/08495	29 May 1992	PCT					
	B2	WO 95/05468	23 February 1995	PCT					
	B3	WO 96/18412	20 June 1996	PCT					
	B4	WO 97/00319	3 January 1997	PCT					
	B5	WO 97/20062	5 June 1997	PCT					
	B6	WO 97/33617	18 September 1997	PCT					
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
	C1	M. Mark, et al.: "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 36, 25 December 1992, pages 26166-26171.							

7-17-02



2	C2	S. Gillies, et al.: "Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins." BIOCONJUGATE CHEMISTRY, 1993 May-June, 4 (3) pages 230-235.
2	C3	Xin Xiao Zheng, et al.: "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation." J. IMMUNOLOGY, 1995, 154(10), pages 5590-5600.
2	C4	R.A. Reisfeld, et al.: "Recombinant antibody fusion proteins for cancer immunotherapy." CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, (1996) 213 (PT 3) pages 27-53. REF: 67.
2	C5	E.T. Harvill, et al. "In vivo properties of an IgG3-IL-2 fusion protein: A general strategy for immune potentiation." JOURNAL OF IMMUNOLOGY. (1996 October 1) 157 (7) pages 3165-3170.
2	C6	G. Lieschke, et al.: "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo." NATURE BIOTECHNOLOGY, vol. 15, no. 1, January 1997, pages 35-40.
2	C7	T. Kim, et al.: "An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production." THE JOURNAL OF IMMUNOLOGY, vol. 158, no. 9, 1 May 1997, pages 4137-4144.
2	C8	S. Gillies, et al.: "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases." THE JOURNAL OF IMMUNOLOGY, vol. 160, no. 12, 15 June 1998, pages 6195-6203.
2	C9	S.D. Gillies, et al.: "Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors." CANCER RESEARCH. (1999 May 1) 59 (9) pages 2159-2166.
EXAMINER 		DATE CONSIDERED 7-17-02

WALLER4006/13.867180-1